Search clinical trials for: DLI

Total 106 results

University of Pennsylvania

Terminated

Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant

Multiple Myeloma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease

United States
Centre Hospitalier Universitaire, Amiens

Unknown

Detection of Urinary Stones on ULDCT With Deep-learning Image Reconstruction Algorithm (URO DLIR)

Renal Colic | Urolithiasis | Urinary Tract Stones | Deep Learning Reconstruction

France
Heinrich-Heine University, Duesseldorf
Celgene Corporation

Completed

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (AZALENA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Germany
Abramson Cancer Center of the University of Pennsylvania

Completed

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

Leukemia

United States
King's College Hospital NHS Trust

Unknown

Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (PRO-DLI)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
University of Freiburg

Completed

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

Acute Myeloid Leukemia, in Relapse

Germany
Peking University People's Hospital

Unknown

Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant

Acute Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion | Graft-versus-host Disease

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Completed

MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion

China
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
University of Wisconsin, Madison
Miltenyi Biomedicine GmbH

Terminated

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Leukemia | Solid Tumors

United States
Masonic Cancer Center, University of Minnesota

Terminated

Post Transplant Donor Lymphocyte Infusion

Multiple Myeloma | AML | Myelodysplastic Syndrome | Leukemia, Lymphocytic, Acute | Lymphomas | Leukemia, Myeloid, Chronic | Leukemia, Lymphocytic, Chronic

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals

Terminated

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Leukemia | Myeloma | Myeloproliferative Diseases

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
University College, London

Unknown

Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers (ProT4)

Lymphoma | Leukemia | Myelodysplastic Syndrome | Myeloma | Graft Versus Host Disease

United Kingdom
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Lymphoma | Leukemia | Myeloproliferative Disorders | Myelodysplastic Syndrome | Multiple Myleoma

United States
Chinese PLA General Hospital

Unknown

Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies

Peripheral Blood Stem Cell Transplantation | Relapse | Donor Lymphocyte Infusion | Graft-versus-host Disease | Decitabine

China
Groupe Francophone des Myelodysplasies

Unknown

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Nanfang Hospital of Southern Medical University

Unknown

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

China
Institut Paoli-Calmettes

Completed

Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation (DLI-NK)

Hematological Malignancy

France
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Hematopoietic/Lymphoid Cancer

United States
M.D. Anderson Cancer Center

Terminated

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Myeloma

United States
National Cancer Institute (NCI)

Terminated

Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemias | Multiple Myeloma With Plasmacytoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Hematologic Malignancy

United States
Mitchell Horwitz, MD

Completed

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Hematological Malignancies

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Malignant Neoplasm

United States
St. Jude Children's Research Hospital

Terminated

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Hematological Malignancies

United States
Masonic Cancer Center, University of Minnesota

Completed

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

AML | MDS | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, Chronic

United States
Wenzhou Medical University

Unknown

Dysfunctional Lens Index Serves as a Novel Surgery Decision Maker for Age-related Cataracts

Age-related Cataract

China
Nelson Chao

Terminated

Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT

Cytomegalovirus Infections

United States
David Rizzieri, MD

Completed

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

Lymphoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Leukemia | Hematologic Malignancies | Myeloma | Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes | Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Lymphoma | Leukemia | Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | AML | Acute Myelogenous Leukemia | Hematologic Malignancy | Myeloma | Non-hodgkin's Lymphoma | CLL | ALL

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Sickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Aplastic Anemia | Hodgkin's Disease | Biphenotypic Leukemia | Plasma Cell Neoplasms

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

Hematologic Malignancies

United States
Dana-Farber Cancer Institute
Miltenyi Biomedicine GmbH

Completed

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

Hematologic Malignancies

United States
Peking University People's Hospital

Unknown

Interferon-α After DLI for the Prevention of Relapse (IDPR-HSCT)

Leukemia

China
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Recurrent Adult Acute Myeloid Leukemia

China
Nantes University Hospital

Completed

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (VIDAZA-DLI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
M.D. Anderson Cancer Center

Terminated

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Lymphoma | Leukemia | Myeloma | Myeloproliferative Diseases

United States
Chinese PLA General Hospital
Navy General Hospital, Beijing

Completed

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

AML | MDS

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT

Acute Leukemia

China
Yale University
Boston Scientific Corporation; Medtronic; Abbott Medical Devices

Completed

Safety of Sports for Patients With Implantable Cardioverter-Defibrillators

Heart Arrhythmias

United States, Belgium, Canada, Switzerland, Israel, Netherlands, Germany, Australia, Czech Republic, France, Norway, Poland, Spain, United Kingdom
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Peking University People's Hospital

Completed

New Therapy for Advanced Stage Leukemia After Stem Cell Transplantation

Leukemia

China
David Rizzieri, MD

Completed

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT

Lymphoma

United States
National University Hospital, Singapore
Singapore General Hospital

Unknown

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Singapore
University Hospital, Clermont-Ferrand
Pierre Fabre Laboratories

Unknown

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia (RICAC)

Chronic Lymphocytic Leukemia | Lymphocytic Lymphoma

France
M.D. Anderson Cancer Center
Eligix

Terminated

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Multiple Myeloma | Chronic Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Leukemia

United States

Search clinical trials for: DLI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations